Exicure, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update

07:00 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Exicure, Inc., a Delaware corporation (the “Company”), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional Spherical Nucleic Acid (SNA™) constructs, today reported its financial results f...

Other Sources for this Article

MacDougall Biomedical Communications
Karen Sharma, 781-235-3060


More From BioPortfolio on "Exicure, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update"

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...